Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer

@article{Urbinati2015AntineoplasticEO,
  title={Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer},
  author={Giorgia Urbinati and H. M. Ali and Q. Rousseau and Hubert Chapuis and D. Desma{\"e}le and P. Couvreur and L. Massaad-Massade},
  journal={PLoS ONE},
  year={2015},
  volume={10}
}
TMPRSS2-ERG junction oncogene is present in more than 50% of patients with prostate cancer and its expression is frequently associated with poor prognosis. Our aim is to achieve gene knockdown by siRNA TMPRSS2-ERG and then to assess the biological consequences of this inhibition. First, we designed siRNAs against the two TMPRSS2-ERG fusion variants (III and IV), most frequently identified in patients’ biopsies. Two of the five siRNAs tested were found to efficiently inhibit mRNA of both TMPRSS2… Expand
Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide
TLDR
These results confirm the therapeutic effectiveness of squalenoyl siRNA nanomedicine for PCa based on siRNA TMPRSS2-ERG and compare or combine the developed siRNA to flutamide (FLU), one of the gold-standard treatment of PCa. Expand
Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1.
The relationship of TMPRSS2-ERG fusion gene with matrix metalloproteinase-9 (MMP-9) and PLXNB1 (plexin B1) in regulation of prostate cancer (PCa) aggressiveness was investigated. Fluorescence in situExpand
Identification of TMPRSS 2-ERG mechanisms in prostate cancer invasiveness : Involvement of MMP-9 and plexin B 1
The relationship of TMPRSS2-ERG fusion gene with matrix metalloproteinase-9 (MMP-9) and PLXNB1 (plexin B1) in regulation of prostate cancer (PCa) aggressiveness was investigated. Fluorescence in situExpand
High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases
TLDR
A high degree of concordance of the ERG expression status between primary prostate cancer types and their lymph node metastases is revealed, suggesting that potential anti-ERG therapy may also be effective against lymph nodes metastases in the majority of cases of ERG-positive metastatic prostate cancer. Expand
An investigation into the function and regulation Of ERG Exon 7b
TLDR
Evidence that exon 7b enhances the oncogenic activity of ERG is provided and it is confirmed that SSOs can be used to modify the splicing of key oncogenes, significantly affecting their function. Expand
Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression
TLDR
In conclusion, functional studies of fusion oncogenes at relapse are of great importance to define mechanisms involved in tumor progression and resistance to conventional treatments. Expand
Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer
TLDR
The development of nontoxic novel monotherapies for targeting TE mRNA in PCa patients and for increasing the clinical efficacy of docetaxel treatment are needed. Expand
Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status
TLDR
Quantitative evaluation of IGF-1/IGF-1R expression combined with molecular assessment of T2E status or ERG protein expression represents a useful marker for tumor progression in localized PCa. Expand
Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer
TLDR
The efficacy, specificity, and delivery of si RNAs are comprehensively discussed in this review to direct further studies toward using siRNAs and their nanoscale-delivery systems in PCa therapy and perhaps other cancer types. Expand
RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine
TLDR
Targeting F3-T3 using siRNAs specific to the fusion breakpoint is capable of eradicating F3T3+ cancers without toxicity related to inhibition of WT FGFR3 or TACC3, and UC-MSC exosomes may be a plausible vehicle to deliver iF3T 3. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 43 REFERENCES
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation
TLDR
Evaluation of the transcriptome and specific gene promoters in ERG siRNA-treated cells and investigation of gene expression signatures of human prostate tumors revealed ERG-mediated activation of C-MYC oncogene and the repression of prostate epithelial differentiation genes (PSA and SLC45A3/Prostein). Expand
TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.
TLDR
This work shows that the TMPRSS2-ERG gene fusion product binds to the ERG locus and drives the overexpression of wild-type ERG in prostate cancers, and provides novel insights into the regulation of ERg in human prostate cancers. Expand
Overexpression of truncated ERG from TMPRSS2-ERG fusion and prostate cancer development
TLDR
Results from ERG target gene expression profile indicate that TMPRSS2-ERG fusion-induced aberrant ERG overexpression indicates that the minor deletion on the N-terminus does not appear to affect the structure or function of ERG. Expand
Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors
TLDR
Targeting the T/E fusion junction in vivo with specific siRNAs delivered via liposomal nanovectors is a promising therapy for men with prostate cancer. Expand
Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression
TLDR
This study indicates that the expression of TMPRSS2:ERG fusion gene among prostate cancer patients treated with surgery is a strong prognostic factor for disease relapse, and may have important clinical implications. Expand
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts.
TLDR
The results indicate that TMPRSS2/ERG fusion isoforms have variable biological activities promoting tumor initiation and progression and are consistent with previous clinical observations indicating that certain TMPR SS2-ERG fusionisoforms are significantly correlated with more aggressive disease. Expand
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
TLDR
Both the isoforms of TMPRSS2/ERG fusions expressed and expression level may affect prostate cancer progression, and in this group, higher expression levels of fusion mRNA were present in cancers with early prostate-specific antigen recurrence. Expand
Effects of siRNA on RET/PTC3 Junction Oncogene in Papillary Thyroid Carcinoma: From Molecular and Cellular Studies to Preclinical Investigations
TLDR
The findings highly support the use of siRNA RET/PTC3-SQ NPs as a new promising treatment for patients affected by PTC expressing RET/ PTC3. Expand
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
TLDR
The findings suggest that TMPRSS2-ERG with Edel is an aggressive and uniformly lethal molecular subtype of prostate cancer associated with androgen-independent disease. Expand
Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia
TLDR
The results suggest that prostate cancer cells in vivo may need Omi/HtrA2 expression for apoptosis, and that Omi /Htr a2 expression might be involved in prostate cancer development. Expand
...
1
2
3
4
5
...